Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2016

Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2016
Published Jun 15, 2016
31 pages — Published Jun 15, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2016, provides in depth analysis on Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) targeted pipeline therapeutics.

The report provides comprehensive information on the Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.)
- The report reviews Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for

  
Source:
Document ID
GMDHC0116TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Overview61
Therapeutics Development73
  Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Products under Development by Stage of Development71
  Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Products under Development by Therapy Area81
  Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Products under Development by Indication91
Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Pipeline Products Glance101
  Early Stage Products101
Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Products under Development by Companies112
Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Therapeutics Assessment136
  Assessment by Monotherapy/Combination Products131
  Assessment by Mechanism of Action141
  Assessment by Route of Administration152
  Assessment by Molecule Type172
Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Companies Involved in Therapeutics Development193
  Paradigm Biopharmaceuticals Limited191
  Pfizer Inc.201
  Takeda Pharmaceutical Company Limited211
Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Drug Profiles226
  Pelladerm Drug Profile221
  pentosan polysulfate sodium Drug Profile231
  PF-152 Drug Profile241
  Small Molecules to Inhibit MMP for Myocardial Infarction Drug Profile251
  Small Molecules to Inhibit MMP-13 for Osteoarthritis Drug Profile261
  Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation Drug Profile271
Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Dormant Projects281
Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) Discontinued Products291
Appendix302
  Methodology301
  Coverage301
  Secondary Research301
  Primary Research301
  Expert Panel Validation301
  Contact Us301
  Disclaimer311

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Collagenase-3-Matrix-Metalloproteinase-13-or-MMP13-or-EC-3-4-24-Pipeline-Review-H1-2016-2088-15977>
  
APA:
Global Markets Direct - Market Research. (2016). Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Collagenase-3-Matrix-Metalloproteinase-13-or-MMP13-or-EC-3-4-24-Pipeline-Review-H1-2016-2088-15977>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.